Colorectal cancer in elderly patients: From best supportive care to cure

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 9, 2013, Pages 1332-1343

  Berretta, Massimiliano ^a   Benedetto, Fabrizio Di ^b   Francia, Raffaele Di ^c   Menzo, Emanuele Lo ^d   Palmeri, Sergio ^e   De Paoli, Paolo ^a   Tirelli, Umberto ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PALERMO   (Italy)

Author keywords

Cancer; Chemotherapy; Colorectal; Elderly; Treatment

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PANITUMUMAB; UFT; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ANOREXIA; ARTICLE; ASTHENIA; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COMORBIDITY; CONFUSION; CREATININE CLEARANCE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EDEMA; FATIGUE; GASTROINTESTINAL DISEASE; GERIATRIC ASSESSMENT; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPOMAGNESEMIA; MACULOPAPULAR RASH; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; AGED; CHEMISTRY; COLORECTAL NEOPLASMS; HEALTH CARE QUALITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; HUMANS; QUALITY OF HEALTH CARE;

EID: 84888214777     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/18715206113136660350     Document Type: Article

References (124)

1. Aapro, M.S.; Kohne, C.H.; Cohen, H.J.; Extermann, M. Never too old? Age should not be a barrier to enrolment in cancer clinical trials. Oncologist, 2005, 10, 198-204.
2. Berrino, F.; Capoccaccia, R.; Esteve, J.; Gatta, G. Survival of Cancer Patients in Europe: The EUROCARE-2 Study. Lyon: IARC 1999.
3. Biganzoli, L.; Aapro, M. Adjuvant chemotherapy in the elderly. Ann. Oncol., 2003, 14 (Suppl 3), iii1-iii3.
4. Surbone, A.; Kagawa-Singer, M.; Terret, C.; Baider, L. The illness trajectory of elderly cancer patients across cultures: SIOG position paper. Ann. Oncol., 2007, 18, 633-638.
5. Fentiman, I.S. Are the elderly receiving appropriate treatment for cancer? Ann. Oncol., 1996, 7, 657-658.
6. Hutchins, L.F.; Unger, J.M.; Crowley, J.J.; Coltman, C.A. Jr.; Albain, K.S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med., 1999, 341, 2061-2067.
7. Chiara, S.; Nobile, M.T.; Vincenti, M.; Lionetto, R.; Gozza, A.; Barzacchi, M.C.; Sanguineti, O.; Repetto, L.; Rosso, R. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother. Pharmacol., 1998, 42, 336-340.
8. Feliu, J.; González Barón, M.; Espinosa, E.; García Girón, C.; de la Gándara, I.; Espinosa, J.; Colmenarejo, A.; Jalón, J.I.; Fernández, Y.; de Castro, J. Uracil and tegafur modulated with leucovorin. An effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Cancer, 1997, 79, 1884-1889.
9. Feliu, J; Mel, J.R.; Camps, C.; Escudero, P.; Aparicio, J.; Menéndez, D.; García Girón, C.; Rodriguez, M.R.; Sánchez, J.J.; González Barón, M.; Oncopaz Cooperative Group Associated Hospitals. Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen. Eur. J. Cancer, 2002, 38, 1204-1211.
10. Abada, A.; Arandab, E.; Navarroc, M.; Carratod, A.; Sastree, J.; Gallénf, M.; Marcuellog, E.; Fernández-Martosh, C.; Cervantesi, A.; Antónj, A.; Riverak, F.; Massutíl, B.; Barnetob, I.; Guillota, M.; Díaz-Rubioe E.; For the TTD Spanish Cooperative Group. Two consecutive studies using oral UFT-based chemotherapy regimens in elderly patients with advanced colorectal cancer. Rev. Oncol., 2000, 2, 154-158.
11. Magné, N.; François, E.; Broisin, L.; Guardiola, E.; Ramaïoli, A.; Ferrero, J.M.; Namer, M. Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly. Results of a 10-year experience. Am. J. Clin. Oncol., 2002, 25, 126-130.
12. Unger, J.M.; Coltman, C.A. Jr.; Crowley, J.J.; Hutchins, L.F.; Martino, S.; Livingston, R.B.; Macdonald, J.S.; Blanke, C.D.; Gandara, D.R.; Crawford, E.D.; Albain, K.S. Impact of the year 2000 Medicare policy change on older patient enrolment to cancer clinical trials. J. Clin. Oncol., 2006, 24, 141-144.
13. Mitry, E.; Douillard, J.Y.; Van Cutsem, E.; Cunningham, D.; Magherini, E.; Mery-Mignard, D.; Awad, L.; Rougier, P. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann. Oncol., 2004, 15, 1013-1017.
14. Rosati, G.; Cordio, S.; Tucci, A.; Blanco, G.; Bordonaro, R.; Reggiardo, G.; Manzione, L. Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients. Oncology, 2005, 69, 122-129.
15. Sastre, J.; Marcuello, E.; Masutti, B.; Navarro, M.; Gil, S.; Antón, A.; Abad, A.; Aranda, E.; Maurel, J.; Valladares, M.; Maestu, I.; Carrato, A.; Vicent, J.M.; Díaz-Rubio, E.; Cooperative Group for the Treatment of Digestive Tumors. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. J. Clin. Oncol., 2005, 23, 3545-3551.
16. Twelves, C.J.; Butts, C.A.; Cassidy, J.; Conroy, T.; Braud, F.D.; Diaz-Rubio, E.; Tabernero, J.M.; Schoffski, P.; Figer, A.; Brunet, R.; Grossmann, J.; Sobrero, A.F.; Van Cutsem, E.J. Capecitabine/ oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study. Clin. Colorectal. Cancer., 2005, 5, 101-107.
17. Feliu, J.; Salud, A.; Escudero, P.; Lopez-Gómez, L.; Bolaños, M.; Galán, A.; Vicent, J.M.; Yubero, A.; Losa, F.; De Castro, J.; de Mon, M.A.; Casado, E.; González-Barón, M. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br. J. Cancer, 2006, 94, 969-975.
18. Comella, P.; Natale, D.; Farris, A.; Gambardella, A.; Maiorino, L.; Massidda, B.; Casaretti, R.; Tafuto, S.; Lorusso, V.; Leo, S.; Cannone, M. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma. Cancer,2005, 104, 282-289.
19. Goldberg, R.M.; Sargent, D.J.; Morton, R.F.; Fuchs, C.S.; Ramanathan, R.K.; Williamson, S.K.; Findlay, B.P.; Pitot, H.C.; Alberts, S.R. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol., 2004, 22(1), 23-30.
20. Balducci, L. Management of cancer in the elderly. Oncology, 2006, 20, 135-143.
21. Sargent, D.J.; Goldberg, R.M.; Jacobson, S.D.; Macdonald, J.S.; Labianca, R.; Haller, D.G.; Shepherd, L.E.; Seitz, J.F.; Francini, G. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N. Engl. J. Med., 2001, 345, 1091-1097.
22. Sundararajan, V.; Mitra, N.; Jacobson, J.S.; Grann, V.R.; Heitjan, D.F.; Neugut, A.I. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with nodepositive colon cancer. Ann. Intern. Med., 2002, 136, 349-357.
23. Jessup, J.M.; Stewart, A.; Greene, F.L.; Minsky, B.D. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. J.A.M.A., 2005, 294, 2703-2711.
24. Scheithauer, W.; McKendrick, J.; Begbie, S.; Borner, M.; Burns, W.I.; Burris, H.A.; Cassidy, J.; Jodrell, D.; Koralewski, P.; Levine, E.L.; Marschner, N.; Maroun, J.; Garcia-Alfonso, P.; Tujakowski, J.; Van Hazel, G.; Wong, A.; Zaluski, J.; Twelves, C.; X-ACT Study Group. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann. Oncol., 2003, 14, 1735-1743.
25. Lemmens, V.E.P.P.; van Halteren, A.H.; Janssen-Heijnen, M.L.G.; Vreugdenhil, G.; Repelaer van Driel, O.J.; Coebergh, W.W. Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomics status, gender, and comorbidity. Ann. Oncol., 2005, 16(5), 767-772.
26. Lembersky, B.C.; Wieand, H.S.; Petrelli, N.J.; O'Connell, M.J.; Colangelo, L.H.; Smith, R.E.; Seay, T.E.; Giguere, J.K.; Marshall, M.E.; Jacobs, A.D.; Colman, L.K.; Soran, A.; Yothers, G.; Wolmark, N. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J. Clin. Oncol., 2006, 24, 2059-2064.
27. Popescu, R.A.; Norman, A.; Ross, P.J.; Parikh, B.; Cunningham, D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J. Clin. Oncol., 1999, 17, 2412-2418.
28. Goldberg, R.M.; Tabah-Fisch, I.; Bleiberg, H.; de Gramont, A.; Tournigand, C.; Andre, T.; Rothenberg, M.L.; Green, E.; Sargent, D.J. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J. Clin. Oncol., 2006, 24, 4085-4091.
29. Neugut, A.I.; Matasar, M.; Wang, X.; McBride, R.; Jacobson, J.S.; Tsai, W.Y.; Grann, V.R.; Hershman, D.L. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J. Clin. Oncol., 2006, 24, 2368-2375.
30. Quasar Collaborative Group; Gray, R.; Barnwell, J.; McConkey, C.; Hills, R.K.; Williams, N.S.; Kerr, D.J. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet, 2007, 370, 2020-2029.
31. Kurtz, J.E.; Heitz, D.; Serra, S.; Brigand, C.; Juif, V.; Podelski, V.; Meyer, P.; Litique, V.; Bergerat, J.P.; Rohr, S.; Dufour, P. Adjuvant chemotherapy in elderly patients with colorectal cancer. A retrospective analysis of the implementation of tumor board recommendations in a single institution. Crit. Rev. Oncol. Hematol., 2010, 74(3), 211-217.
32. Wildes, T.M.; Kallogjeri, D.; Powers, B.; Vlahiotis, A.; Mutch, M.; Spitznagel, E.L. Jr.; Tan, B.; Piccirillo, J.F. The Benefit of Adjuvant Chemotherapy in Elderly Patients with Stage III Colorectal Cancer is Independent of Age and Comorbidity. J. Geriatr. Oncol., 2010, 1(2), 48-56.
33. André, T.; Boni, C.; Mounedji-Boudiaf, L.; Navarro, M.; Tabernero, J.; Hickish, T.; Topham, C.; Zaninelli, M.; Clingan, P.; Bridgewater, J.; Tabah-Fisch, I.; de Gramont, A.; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med., 2004, 350(23), 2343-2351.
34. de Gramont, A.; Boni, C.; Navarro, M.; Tabernero, J.; Hickish, T.; Topham, C.; Bonetti, A.; Clingan, P.; Lorenzato, C.; Andrè, T. Oxaliplatin/5FU/LVin adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. Proc. Am. Soc. Clin. Oncol. J. Clin. Oncol., 2007, 25(18S), 4007. (Abstract).
35. Jackson McCleary, N.A.; Meyerhardt, J.; Green, E.; Yothers, G.; de Gramont, A.; Van Cutsem, E.; O'Connell, M.; Twelves, C.; Saltz, L.; Sargent, D.; and The ACCENT Collaborative Group. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database. Proc. Am. Soc. Clin. Oncol. J. Clin. Oncol., 2009, 27(15S), 4010. (Abstract).
36. Sanoff, H.K.; Carpenter, W.R.; Stürmer, T.; Goldberg, R.M.; Martin, C.F.; Fine, J.P.; McCleary, N.J.; Meyerhardt, J.A.; Niland, J.; Kahn, K.L.; Schymura, M.J.; Schrag, D. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J. Clin. Oncol., 2012, 30(21), 2624-2634.
37. Tourningard, C.; Andrè, T.; Bonnetain, F.; Chibaudel, B.; Lledo, G.; Hickish, T.; Tabernero, J.; Boni, C.; Bachet, J.B.; Teixeira, L.; de Gramnt, A. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer. Subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant treatment of colon cancer trial. J. Clin. Oncol., 2012, 30, 3353-3360.
38. Venook, A. Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist, 2005, 10, 250-261.
39. Berretta, M.; Zanet, E.; Nasti, G.; Lleshi, A.; Frustaci, S.; Fiorica, F.; Bearz, A.; Talamini, R.; Lestuzzi, C.; Lazzarini, R.; Fisichella, R.; Cannizzaro, R.; Iaffaioli, R.V.; Berretta, S.; Tirelli, U. Oxaliplatin-based chemotherapy in the treatment of elderly patients with metastatic colorectal cancer (CRC). Arch. Gerontol. Geriatr., 2012, 55(2), 271-275.
40. Berretta, M.; Cappellani, A.; Fiorica, F.; Nasti, G.; Frustaci, S.; Fisichella, R.; Bearz, A.; Talamini, R.; Lleshi, A.; Tambaro, R.; Cocciolo, A.; Ristagno, M.; Bolognese, A.; Basile, F.; Meneguzzo, N.; Berretta, S.; Tirelli, U. FOLFOX4 in the treatment of metastatic colorectal cancer in elderly patients: a prospective study. Arch. Gerontol. Geriatr., 2011, 52(1), 89-93.
41. Berretta, M.; Bearz, A.; Frustaci, S.; Talamini, R.; Lombardi, D.; Fratino, L.; Lleshi, A.; Bonanno, S.; Spartà, D.; Palmucci, S.; Berretta, S.; Tirelli, U. FOLFOX2 in the treatment of advanced colorectal cancer: a comparison between elderly and middle aged patients. J. Chemother., 2008, 20(4), 503-508.
42. Yee, K.W.; Pater, J.L.; Pho, L.; Zee, B.; Siu, L.L. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J. Clin. Oncol., 2003, 21, 1618-1623.
43. Extermann, M.; Albrand, G.; Chen, H.; Zanetta, S.; Schonwetter, R.; Zulian, G.B.; Cantor, A.; Droz, J.P. Are older French patients as willing as older American patients to undertake chemotherapy? J. Clin. Oncol., 2003, 21, 3214-3219.
44. Folprecht, G.; Seymour, T.; Saltz, L.; Douillard, J.Y.; Stephens, R.J.; Van Cutsem, E.; Rougier, P.; Maughan, T.S.; Kohne, C.H.; and Irinotecan Meta-analysis Group. Irinotecan/5-FU/FA (I-FU) or FU/FA (FU) first-line therapy in older and younger patients with metastatic colorectal cancer: combined analysis of 2.691 patients in randomized controlled trials. Proc. Am. Soc. Clin. Oncol. J. Clin. Oncol., 2007, 25(18S), 4071. (Abstract).
45. Yellen, S.B.; Cella, D.F.; Leslie, W.T. Age and clinical decision making in oncology patients. J. Natl. Canc. Inst., 1994, 86, 1766-1770.
46. Rougier, P.; Mitry, E.; Cunningham, D.; Roth, A.; Clavero-Fabri, M.C.; Magherini, E.; Mery-Mignard, D.; Awad, L.; Douillard, J.Y. Is age a prognostic factor of toxicity and efficacy in patients with metastatic colorectal cancer receiving irinotecan in combination with 5FU/folinic acid (FA). Proc. Am. Soc. Clin. Oncol., 2003, 21, 267. abstract 1072.
47. de Gramont, A.; Figer, A.; Seymour, M.; Homerin, M.; Hmissi, A.; Cassidy, J.; Boni, C.; Cortes-Funes, H.; Cervantes, A.; Freyer, G.; Papamichael, D.; Le Bail, N.; Louvet, C.; Hendler, D.; de Braud, F.; Wilson, C.; Morvan, F.; Bonetti, A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol., 2000, 18, 2938-2947.
48. André, T.; Bensmaine, M.A.; Louvet, C.; François, E.; Lucas, V.; Desseigne, F.; Beerblock, K.; Bouché, O.; Carola, E.; Merrouche, Y.; Morvan, F.; Dupont-André, G.; de Gramont, A. Multicenter phase II study of bimonthly high dose leucovorin, fluorouracil infusion and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J. Clin. Oncol., 1999, 17, 3560-3568.
49. Figer, A.; Perez-Staub, N.; Carola, E.; Tournigand, C.; Lledo, G.; Flesch, M.; Barcelo, R.; Cervantes, A.; André, T.; Colin, P.; Louvet, C.; de Gramont, A. FOLFOX in patients aged between 78 and 80 years with metastatic colorectal cancer. An exploratory cohort of the OPTIMOX study. Cancer, 2007, 110, 2666-2671.
50. Mattioli, R.; Massacesi, C.; Recchia, F.; Marcucci, F.; Cappelletti, C.; Imperatori, L.; Pilone, A.; Rocchi, M.; Cesta, A.; Laici, G.; Bonsignori, M.; Lippe, P. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann. Oncol., 2005, 16, 1147-1151.
51. Souglakos, J.; Pallis, A.; Kakolyris, S.; Mavroudis, D.; Androulakis, N.; Kouroussis, C.; Agelaki, S.; Xenidis, N.; Milaki, G.; Georgoulias, V. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. Oncology, 2005, 69, 384-390.
52. Aparicio, T.; Desramé, J.; Lecomte, T.; Mitry, E.; Belloc, J.; Etienney, I.; Montembault, S.; Vayre, L.; Locher, C.; Ezenfis, J.; Artru, P.; Mabro, M.; Dominguez, S.; AGEO. Oxaliplatin-or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Brit. J. Cancer, 2003, 89, 1439-1444.
53. Beretta, G.; Bollina, R.; Cozzi, C.; Beretta, G. Should we consider weekly (w) chemotherapy with 5-fluorouracil (F) + racemic folinic acid (f) a standard treatment for carcinoma of the digestive tract (DTD) in elderly patients. Proc. Am. Soc. Clin. Oncol., 1997, 920.
54. Folprecht, G.; Cunningham, D.; Ross, P.; Glimelius, B.; Di Costanzo, F.; Wils, J.; Scheithauer, W.; Rougier, P.; Aranda, E.; Hecker, H.; Köhne, C.H. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann. Oncol., 2004, 15, 1330-1338.
55. Barton, M.; Gabriel, G.; Alam, M.; Eek, R. Discrimninating factors in treatment decisons for chemotherapy in elderly patients with colorectal cancer. Cancer Forum, 2008, 32(1), 22-26.
56. National Cancer database. Commission on Cancer. ACoS. Benchmark Reports, v1.1, October 1, 2007.
57. Ho, C.; Ng, K.; O'Reilly, S.; Gill, S. Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis. Clin. Colorectal. Cancer, 2005, 5(4), 279-282.
58. Khattak, M.A.; Townsend, A.R.; Beeke, C.; Karapetis, C.S.; Luke, C.; Padbury, R.; Maddern, G.; Roder, D.; Price, T.J. Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer. Eur. J. Cancer, 2012, 48(9), 1293-1298.
59. Stein, B.N.; Petrelli, N.J.; Douglass, H.O.; Driscoll, D.L.; Arcangeli, G.; Meropol, N.J. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer, 1995, 75(1), 11-17.
60. Köhne, C.H.; Cunningham, D.; Di Costanzo, F.; Glimelius, B.; Blijham, G.; Aranda, E.; Scheithauer, W.; Rougier, P.; Palmer, M.; Wils, J.; Baron, B.; Pignatti, F.; Schöffski, P.; Micheel, S.; Hecker, H. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann. Oncol., 2002, 13(2), 308-317.
61. Kyriakou, F.; Kountourakis, P.; Papamichael, D. Targeted agents: review of toxicity in the elderly metastatic colorectal cancer patients. Target Oncol., 2011, 6(4), 245-251.
62. Cassidy, J.; Douillard, J.Y.; Twelves, C.; McKendrick, J.J.; Scheithauer, W.; Bustová, I.; Johnston, P.G.; Lesniewski-Kmak, K.; Jelic, S.; Fountzilas, G.; Coxon, F.; Díaz-Rubio, E.; Maughan, T.S.; Malzyner, A.; Bertetto, O.; Beham, A.; Figer, A.; Dufour, P.; Patel, K.K.; Cowell, W.; Garrison, L.P. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br. J. Cancer, 2006, 94(8), 1122-1129.
63. Cassidy, J.; Twelves, C.; Van Cutsem, E.; Hoff, P.; Bajetta, E.; Boyer, M.; Bugat, R.; Burger, U.; Garin, A.; Graeven, U.; McKendric, J.; Maroun, J.; Marshall, J.; Osterwalder, B.; Pérez-Manga, G.; Rosso, R.; Rougier, P.; Schilsky, R.L. Capecitabine Colorectal Cancer Study Group. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann. Oncol., 2002, 13(4), 566-575.
64. Van Cutsem, E.; Twelves, C.; Cassidy, J.; Allman, D.; Bajetta, E.; Boyer, M.; Bugat, R.; Findlay, M.; Frings, S.; Jahn, M.; McKendrick, J.; Osterwalder, B.; Perez-Manga, G.; Rosso, R.; Rougier, P.; Schmiegel, W.H.; Seitz, J.F.; Thompson, P.; Vieitez, J.M.; Weitzel, C.; Harper, P.; Xeloda Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J. Clin. Oncol., 2001, 19, 4097-4106.
65. Hoff, P.M.; Ansari, R.; Batist, G.; Cox, J.; Kocha, W.; Kuperminc, M.; Maroun, J.; Walde, D.; Weaver, C.; Harrison, E.; Burger, H.U.; Osterwalder, B.; Wong, A.O.; Wong, R. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J. Clin. Oncol., 2001, 19, 2282-2292.
66. Papamichael, D.; Audisio, R.; Horiot, J.C.; Glimelius, B.; Sastre, J.; Mitry, E.; Van Cutsem, E.; Gosney, M.; Köhne, C.H.; Aapro, M.; SIOG. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann. Oncol., 2009, 20(1), 5-16.
67. Chu, E.; Schulman, K.L.; McKenna, E.F. Jr., Cartwright, T. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison. Clin. Colorectal Cancer., 2010, 9(4), 229-237.
68. Raymond, E.; Faivre, S.; Woynarowski, J.M.; Chaney, S.G. Oxaliplatin: mechanism of action and antineoplastic activity. Semin. Oncol., 1998, 25, 4-12.
69. Lee, J.J.; Chu, E. An update on treatment advances for the first-line therapy of metastatic colorectal cancer. Cancer J., 2007, 13, 276-282.
70. Carrato, A.; Gallego-Plazas, J.; Guillen-Ponce, C. Capecitabine plus oxaliplatin for the treatment of colorectal cancer. Expert Rev. Anticancer. Ther., 2008, 8, 161-174.
71. Rothenberg, M.L.; Oza, A.M.; Bigelow, R.H.; Berlin, J.D.; Marshall, J.L.; Ramanathan, R.K.; Hart, L.L.; Gupta, S.; Garay, C.A.; Burger, B.G.; Le Bail, N.; Haller, D.G. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J. Clin. Oncol., 2003, 21(11), 2059-2069.
72. Figer, A.; Perez, N.; Carola, E.; Andre, T.; Chirivella, I.; Lledo, G.; Flesch, M.; Rivera, F.; Colin P.; De Gramont, A. 5-Fluorouracil, folinic acid and oxaliplatin (FOLFOX) in very old patients with metastatic colorectal cancer. J. Clin. Oncol., 2004, 22(14S), 2004, 3571. [abstract].
73. Mattioli, R.; Massacesi, C.; Recchia, F.; Marcucci, F.; Cappelletti, C.; Imperatori, L.; Pilone, A.; Rocchi, M.; Cesta, A.; Laici, G.; Bonsignori, M.; Lippe, P. High activity and reduced eurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann. Oncol., 2005, 16(7), 1147-1151.
74. Oh, D.-Y.; Kim, Y.-J.; Han, S.-W.; Choi, I.-S.; Kim, J.H.; Kim, D.-W.; Im, S.-A.; Kim, T.-Y.; Heo, D.S.; Bang, Y.-J., Kim, N.K. Efficacy of reduced intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer. J. Clin. Oncol., 2005, 23(16S), 300s, 3720.[abstract].
75. Tabash-Fisch, I.; Maindrault-Goebel, F.; Benavides, M. Oxaliplatin/5FU/LV is feasible, safe and active in elderly colorectal cancer (CRC) patients, Proc. Am. Soc. Clin. Oncol., 2002, 21, 556.
76. Levi, F.; Zidani, R.; Focan, C. Age-independent benefit of chemotherapy with 5-fluorouracil, leucovorin, and oxaliplatin in patients with metastatic colorectal cancer within multi center randomized phase III trials. Proc. Am. Soc. Clin. Oncol., 2002, 21, 1431.
77. Comandone, A.; Pochettino, P.; Bergnolo, P.; Boglione, A.; Dal Canton, O.; Chiado Cutin, S.; Garetto, F.; Biscardi, M.; Oliva, C. Capecitabine and oxaliplatin: A phase II study with a new schedule of administration in elderly patients with advanced colorectal cancer. J. Clin. Oncol., 2005, 23(16S), 291s, 3681.
78. Douillard, J.Y.; Cunningham, D.; Roth, A.D.; Navarro, M.; James, R.D.; Karasek, P.; Jandik, P.; Iveson, T.; Carmichael, J.; Alakl, M.; Gruia, G.; Awad, L.; Rougier, P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 2000, 355(9209), 1041-1047.
79. Chau, I.; Norman, A.R.; Cunningham, D.; Waters, J.S.; Topham, C.; Middleton, G.; Hill, M.; Ross, P.J.; Katopodis, R.; Stewart, G.; Oates, J.R. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br. J. Cancer, 2004, 91(8), 1453-1458.
80. Rothenberg, M.L.; Cox, J.V.; DeVore, R.F.; Hainsworth, J.D.; Pazdur, R.; Rivkin, S.E.; Macdonald, J.S.; Geyer, C.E. Jr.; Sandbach, J.; Wolf, D.L.; Mohrland, J.S.; Elfring, G.L.; Miller, L.L.; Von Hoff, D.D. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer, 1999, 85(4), 786-795.
81. Saltz, L.B.; Cox, J.V.; Blanke, C.; Rosen, L.S.; Fehrenbacher, L.; Moore, M.J.; Maroun, J.A.; Ackland, S.P.; Locker, P.K.; Pirotta, N.; Elfring, G.L.; Miller, L.L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med., 2000, 343(13), 905-914.
82. Mitry, E.; Phelip, J.M.; Bonnetain, F. Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients (FFCD 2001-02 trial): Results of a planned interim analysis. ASCO Gastrointestinal Cancers Symposium. Available at: www.asco.org 2008 (Abstr 281).
83. Köhne, C.H.; van Cutsem, E.; Wils, J.; Bokemeyer, C.; El-Serafi, M.; Lutz, M.P.; Lorenz, M.; Reichardt, P.; Rückle-Lanz, H.; Frickhofen, N.; Fuchs, R.; Mergenthaler, H.G.; Langenbuch, T.; Vanhoefer, U.; Rougier, P.; Voigtmann, R.; Müller, L.; Genicot, B.; Anak, O.; Nordlinger, B.; European Organisation for Research and Treatment of Cancer Gastrointestinal Group. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J. Clin. Oncol., 2005, 23, 4856-4865.
84. Tournigand, C.; André, T.; Achille, E.; Lledo, G.; Flesh, M.; Mery-Mignard, D.; Quinaux, E.; Couteau, C.; Buyse, M.; Ganem, G.; Landi, B.; Colin, P.; Louvet, C.; de Gramont, A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J. Clin. Oncol., 2004, 22, 229-237.
85. Mitry, E.; Tournigand, C.; Andre, T.; Douillard, J.Y.Y.; Louvet, C.; Cunningham, D.; Magherini, E.; Mery-Mignard, D.; De Gramont, A.; Rougier, P. Comparison of the tolerance and efficacy of LV5FU2-CPT11 and FOLFIRI regimens in front-line treatment of advanced colorectal cancer-a pooled analysis of 254 patients included in 2 randomised trials. Proc. Am. Soc. Clin. Oncol., 2004, 22, 3576.
86. Saunders, M.; Iveson, T. Management of advanced colorectal cancer: State of the art. Br. J. Cancer, 2006, 95, 131-138.
87. Souglakos, J.; Pallis, A.; Kakolyris, S.; Mavroudis, D.; Androulakis, N.; Kouroussis, C.; Agelaki, S.; Xenidis, N.; Milaki, G.; Georgoulias, V. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: A phase II trial. Oncology, 2005, 69, 384-390.
88. Folprecht, G.; Rougier, P.; Saltz, L.; Van Cutsem, E.; Douillard, J.Y.; Sastre, J.; Mitry, E.; Hecker, H.; Schubert, U.; Kohne, C.H. Irinotecan in first line therapy of elderly and non-elderly patients with metastatic colorectal cancer: Metaanalysis of three trials investigating 5-FU and irinotecan. Proc. Am. Soc. Clin. Oncol., 2006, 24, 3578.
89. Cunningham, D.; Pyrhönen, S.; James, R.D.; Punt, C.J.; Hickish, T.F.; Heikkila, R.; Johannesen, T.B.; Starkhammar, H.; Topham, C.A.; Awad, L.; Jacques, C.; Herait, P. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 1998, 352, 1413-1418.
90. Rougier, P.; Van Cutsem, E.; Bajetta, E.; Niederle, N.; Possinger, K.; Labianca, R.; Navarro, M.; Morant, R.; Bleiberg, H.; Wils, J.; Awad, L.; Herait, P.; Jacques, C. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet, 1998, 352, 1407-1412.
91. Tournigand, C.; André, T.; Achille, E.; Lledo, G.; Flesh, M.; Mery-Mignard, D.; Quinaux, E.; Couteau, C.; Buyse, M.; Ganem, G.; Landi, B.; Colin, P.; Louvet, C.; de Gramont, A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J. Clin. Oncol., 2004, 22, 229-237.
92. Genentech, Inc., United States Securities and Exchange Commission. Available at: http://www.sec.gov/Archives/edgar/data/318771/000031877109000003/form10-k_2008.htm.
93. Jain, R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med., 2001, 7, 987-989.
94. Wang, Y.; Fei, D.; Vanderlaan, M.A. Song. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis, 2004, 7(4), 335-345.
95. Augustin, H.G. Translating angiogenesis research into the clinic: the challenges ahead. Brit. J. Radiol., 2003, 76 (Spec No 1), S3-S10.
96. Homsi, J.; Daud, A.I. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control J. Moffitt Cancer Center, 2007, 14, 285-294.
97. Lambrechts, D.; Claes, B.; Delmar, P.; Reumers, J.; Mazzone, M.; Yesilyurt, B.T.; Devlieger, R.; Verslype, C.; Tejpar, S.; Wildiers, H.; de Haas, S.; Carmeliet, P.; Scherer, S.J.; Van Cutsem, E. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol., 2012, 13, 724-733.
98. Barrueco, J.; Marshall, J.; Mitchell, E.; Wierzbicki, R.; Ganju, V.; Jeffery, M.; Schultz, J.; Richards, D.; Soufi-Mahjoubi, R.; Fuchs, C. Safety and efficacy of first-line irinotecan/fluoropymidine combinations in mCRC patients >65 years compared with those <65: The BICC-C study. J. Clin. Oncol., 2007, 25 (18S), 4076.
99. Kabbinavar, F.F.; Schulz, J.; McCleod, M.; Patel, T.; Hamm, J.T.; Hecht, J.R.; Mass, R.; Perrou, B.; Nelson, B.; Novotny, W.F. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J. Clin. Oncol., 2005, 23(16), 3697-3705.
100. Kabbinavar, F.F.; Hurwitz, H.I.; Yi, J.; Sarkar, S.; Rosen, O. Addition of bevacizumab to fluorouracil-based first-line treatment of metastaticcolorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J. Clin. Oncol., 2009, 27(2), 199-205.
101. Cassidy, J.; Saltz, L.B.; Giantonio, B.J.; Kabbinavar, F.F.; Hurwitz, H.I.; Rohr, U.P. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J. Cancer. Res. Clin. Oncol., 2010, 136(5), 737-743.
102. Kozloff, M.; Yood, M.U.; Berlin, J.; Flynn, P.J.; Kabbinavar, F.F.; Purdie, D.M.; Ashby, M.A.; Dong, W.; Sugrue, M.M.; Grothey, A.; Investigators of the BRiTE study. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist, 2009, 14(9), 862-870.
103. Kozloff, M.F.; Berlin, J.; Flynn, P.J.; Kabbinavar, F.; Ashby, M.; Dong, W.; Sing, A.P.; Grothey, A. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology, 2010, 78(5-6), 329-339.
104. Van Cutsem, E.; Rivera, F.; Berry, S.; Kretzschmar, A.; Michael, M.; DiBartolomeo, M.; Mazier, M.A.; Canon, J.L.; Georgoulias, V.; Peeters, M.; Bridgewater, J.; Cunningham, D.; First BEAT investigators. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann. Oncol., 2009, 20(11), 1842-1847.
105. Kubala, E.; Bartos J.; Petruzelka, L.B.; Prausova, J.; Benesova, V.; Gruna, J.; Finek, J.; Twardzikova, P.; Melichar, B.; Kohoutek, M. Safety and effectiveness of bevacizumab (bev) in combination with chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): Results from a large Czech observational registry (CSTP). Proc. Am. Soc. Clin. Oncol. Gastrointest. Cancer. Symp., 2010, Abstr 467
106. Price, T.J.; Zannino, D.; Wilson, K.; Simes, R.J.; Cassidy, J.; Van Hazel, G.A.; Robinson, B.A.; Broad, A.; Ganju, V.; Ackland, S.P.; Tebbutt, N.C. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomized controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Ann. Oncol., 2012, 23(6), 1531-1536.
107. Kubala, E.; Bartos, J.; Petruzelka, L.B. Safety and effectiveness of bevacizumab in combination with chemotherapy in elderly patients with metastatic colorectal cancer: results from a large Czech observational registry. In: Gastrointestinal Cancers Symposium, 2010, 467.
108. Rosati, G.; Avallone, A.; Aprile, G.; Butera, A.; Reggiardo, G.; Bilancia, D. XELOX and bevacizumab followed by single-agent bevacizumab as maintnenace therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study. Cancer Chemother. Pharmacol., 2013, 71, 257-264.
109. Tsai, H.-T.; Marshall, J.L.; Weiss, S.R; Huang, C.-Y; Warren, J.L.; Freedman, A.N.; Fu, A.Z.; Sansbury, L.B.; Potosky, A.L. Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study. Ann. Oncol., 2013, Feb. 27. [Epub ahead of print].
110. Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; Santoro, A.; Bets, D.; Mueser, M.; Harstrick, A.; Verslype, C.; Chau, I.; Van Cutsem, E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N. Engl. J. Med., 2004, 351, 337-345.
111. Jonker, D.J.; O'Callaghan, C.J.; Karapetis, C.S.; Zalcberg, J.R.; Tu, D.; Au, H.J.; Berry, S.R.; Krahn, M.; Price, T.; Simes, R.J.; Tebbutt, N.C.; van Hazel, G.; Wierzbicki, R.; Langer, C.; Moore, M.J. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med., 2009, 360(14), 1408-1417.
112. Asmis, T.R.; Powell, E.; Karapetis, C.S.; Jonker, D.J.; Tu, D.; Jeffery, M.; Pavlakis, N.; Gibbs, P.; Zhu, L.; Dueck, D.A.; Whittom, R.; Langer, C.; O'Callaghan, C.J. Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)-results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Ann. Oncol., 2011, 22(1), 118-126.
113. Bouchahda, M.; Macarulla, T.; Spano, J.P.; Bachet, J.B.; Lledo, G.; Andre, T.; Landi, B.; Tabernero, J.; Karaboué, A.; Domont, J.; Levi, F.; Rougier, P. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit. Rev. Oncol. Hematol., 2008, 67(3), 255-262.
114. Fornaro, L.; Baldi, G.G.; Masi, G.; Allegrini, G.; Loupakis, F.; Vasile, E.; Cupini, S.; Stasi, I.; Salvatore, L.; Cremolini, C.; Vincenzi, B.; Santini, D.; Tonini, G.; Graziano, F.; Ruzzo, A.; Canestrari, E.; Magnani, M.; Falcone, A. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status. Crit. Rev. Oncol. Hematol., 2011, 78(3), 243-251.
115. Sastre, J.; Aranda, E.; Grávalos, C.; Massutí, B.; Varella-Garcia, M.; Rivera, F.; Soler, G.; Carrato, A.; Manzano, J.L.; Díaz-Rubio, E.; Hidalgo, M. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Crit. Rev. Oncol. Hematol., 2011, 77 (1), 78-84.
116. Van Cutsem, E.; Köhne, C.H.; Hitre, E.; Zaluski, J.; Chang Chien, C.R.; Makhson, A.; D'Haens, G.; Pintér, T.; Lim, R.; Bodoky, G.; Roh, J.K.; Folprecht, G.; Ruff, P.; Stroh, C.; Tejpar, S.; Schlichting, M.; Nippgen, J.; Rougier, P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med., 2009, 360, 1408-1417.
117. Su, X.; Lacouture, M.E.; Jia, Y.; Wu, S. Risk of high-grade skin rash in cancer patients treated with cetuximab-an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology, 2009, 77(2), 124-133.
118. Sobrero, A.F.; Maurel, J.; Fehrenbacher, L.; Scheithauer, W.; Abubakr, Y.A.; Lutz, M.P.; Vega-Villegas, M.E.; Eng, C.; Steinhauer, E.U.; Prausova, J.; Lenz, H.J.; Borg, C.; Middleton, G.; Kröning, H.; Luppi, G.; Kisker, O.; Zubel, A.; Langer, C.; Kopit, J.; Burris, H.A. 3rd. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol., 2008, 26(14), 2311-2319.
119. Siena, S.; Glynne-Jones, R.; Adenis, A.; Thaler, J.; Preusser, P.; Aguilar, E.A.; Aapro, M.S.; Loos, A.H.; Esser, R.; Wilke, H. Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. Cancer, 2010, 116(7), 1827-1837.
120. Tejpar, S.; Piessevaux, H.; Claes, K.; Piront, P.; Hoenderop, J.G.; Verslype, C.; Van Cutsem, E. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol., 2007, 8(5), 387-394.
121. Schrag, D.; Chung, K.Y.; Flombaum, C.; Saltz, L. Cetuximab therapy and symptomatic hypomagnesemia. J. Natl. Cancer Inst., 2005, 97(16), 1221-1224.
122. Kyriakou, F.; Kountourakis, P.; Papamichael, D. Targeted agents: review of toxicity in the elderly metastatic colorectal cancer patients. Targ. Oncol., 2011, 6, 245-251.
123. Heun, J.; Holen, K. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Clin. Colorectal Cancer, 2007, 6(7), 529-531.
124. Cartwright, T.H.; Genther, R. Successful administration of panitumumab alone after severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer. Clin. Colorectal Cancer, 2008, 7(3), 202-203.